Supernus Pharmaceuticals (SUPN) Net Margin (2016 - 2025)
Historic Net Margin for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Q3 2025 value amounting to 23.49%.
- Supernus Pharmaceuticals' Net Margin fell 454000.0% to 23.49% in Q3 2025 from the same period last year, while for Sep 2025 it was 2.8%, marking a year-over-year decrease of 119500.0%. This contributed to the annual value of 11.16% for FY2024, which is 109400.0% up from last year.
- Supernus Pharmaceuticals' Net Margin amounted to 23.49% in Q3 2025, which was down 454000.0% from 13.6% recorded in Q2 2025.
- Supernus Pharmaceuticals' Net Margin's 5-year high stood at 21.91% during Q3 2024, with a 5-year trough of 23.49% in Q3 2025.
- Over the past 5 years, Supernus Pharmaceuticals' median Net Margin value was 4.6% (recorded in 2022), while the average stood at 5.28%.
- Per our database at Business Quant, Supernus Pharmaceuticals' Net Margin soared by 323200bps in 2024 and then tumbled by -454000bps in 2025.
- Quarter analysis of 5 years shows Supernus Pharmaceuticals' Net Margin stood at 1.54% in 2021, then soared by 892bps to 15.23% in 2022, then tumbled by -95bps to 0.72% in 2023, then soared by 1135bps to 8.83% in 2024, then crashed by -366bps to 23.49% in 2025.
- Its Net Margin stands at 23.49% for Q3 2025, versus 13.6% for Q2 2025 and 7.9% for Q1 2025.